Statement: The majority of patients in the primary trial experienced at least one adverse event.
Primary_evidence: Adverse Events 1:   Total: 20/88 (22.73%)   Cardiac Failure * 2/88 (2.27%)   Intracardiac thrombus * 1/88 (1.14%)   Abdominal pain * 1/88 (1.14%)   Diarrhoea * 2/88 (2.27%)   Enteritis * 1/88 (1.14%)   Intestinal perforation * 1/88 (1.14%)   Chest pain * 1/88 (1.14%)   Death * 1/88 (1.14%)   Erysipelas * 1/88 (1.14%)   Pneumonia * 1/88 (1.14%)   Abdominal wound dehiscence * 1/88 (1.14%)